Isomorphic Labs has closed an oversubscribed $5 billion Series C to scale its AI drug-design engine, IsoDDE, and expand a growing therapeutic candidate pipeline toward clinical testing. The round follows a $1.2 billion Series B six months earlier and further underscores how venture capital is accelerating compute- and simulation-heavy approaches to small-molecule discovery. The financing is co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and continued investment from Alphabet and prior backers. Isomorphic says the funds will support scaling the core design engine, broadening model coverage, and building translational and clinical infrastructure to support rapid candidate iteration. In parallel, Merck has entered a research collaboration with Isomorphic to discover small-molecule oncology candidates for an undisclosed “strategic importance” target. The structure places Merck in control of preclinical/clinical development, manufacturing, and commercialization, while Isomorphic provides proprietary drug-design capabilities. Together, the two moves suggest platform validation is increasingly driven by both mega-round funding and pharma partnerships that translate model outputs into preclinical development pipelines.
Get the Daily Brief